SeaStar Medical Finalizes Registration for $14.6M Equity Line, Enabling Significant Dilution for Critical Capital

summarizeSummary

SeaStar Medical has finalized the registration for an existing equity line agreement, allowing it to sell up to an additional $14.6 million in common stock to Lincoln Park Capital, providing critical funding but at the cost of significant shareholder dilution.

check_boxKey Events

• Equity Line Registration Finalized

  This filing finalizes the registration for resale of up to 2,000,000 shares by Lincoln Park Capital Fund, LLC, under an existing purchase agreement established on April 25, 2025.

• Critical Capital Raise

  The company can now raise up to an additional $14.6 million from Lincoln Park, which is crucial for its operations given a recent 'going concern' warning due to limited cash runway.

• Substantial Dilution

  The offering involves significant potential dilution, with the 1,664,543 shares registered for sale to Lincoln Park representing approximately 29.4% of the company's outstanding shares.

• Discounted Share Sales

  Shares will be sold to Lincoln Park at a discount, specifically 97% of the lower of the lowest sale price or the average of the three lowest closing prices over a 10-day period.

auto_awesomeAnalysis

This prospectus finalizes the registration for resale of up to 2,000,000 shares by Lincoln Park Capital Fund, LLC, under an existing purchase agreement dated April 25, 2025. This enables SeaStar Medical to raise up to an additional $14.6 million in capital, which is critical for a company facing a 'going concern' warning due to limited cash. While the capital is essential for extending the company's operational runway, the offering involves substantial potential dilution, with the registered shares representing approximately 29.4% of current outstanding shares, and sales will occur at a discount to market prices.